Welcome to our dedicated page for Johnson & Johnson news (Ticker: JNJ), a resource for investors and traders seeking the latest updates and insights on Johnson & Johnson stock.
Johnson & Johnson (NYSE: JNJ) generates a steady flow of news across Innovative Medicine and MedTech, reflecting its role in pharmaceutical preparation manufacturing and medical technologies. On this news page, readers can follow company announcements on clinical trial results, regulatory milestones, strategic transactions, manufacturing investments and corporate actions.
Recent oncology news includes positive topline data from the Phase 3 MajesTEC-9 study of TECVAYLI (teclistamab-cqyv) monotherapy in relapsed or refractory multiple myeloma, where Johnson & Johnson reported a substantial reduction in the risk of disease progression or death versus standard of care in a population predominantly refractory to anti-CD38 therapy and lenalidomide. The company has also shared longer-term results from the OrigAMI-1 study of RYBREVANT (amivantamab-vmjw) plus chemotherapy in metastatic colorectal cancer, supporting further Phase 3 evaluation of amivantamab-based regimens in first- and second-line settings.
In neuroscience and mental health, Johnson & Johnson has highlighted new data on CAPLYTA (lumateperone), SPRAVATO (esketamine) and the investigational agent seltorexant at major scientific meetings, including analyses focused on remission in major depressive disorder, treatment-resistant depression and sleep-related symptoms. The company has also announced positive Phase 2b results for nipocalimab in systemic lupus erythematosus and plans to initiate a Phase 3 program, underscoring its activity in autoantibody-driven diseases.
MedTech news covers developments such as the FDA submission of the OTTAVA robotic surgical system for De Novo classification, supported by an IDE study in gastric bypass procedures, and an expanded indication for the TRUFILL n‑BCA Liquid Embolic System for chronic subdural hematoma. Corporate and financial updates, including quarterly dividend declarations, U.S. manufacturing investments and government agreements to improve access to medicines, also appear in Johnson & Johnson’s news flow. Investors, clinicians and observers can use this page to monitor how Johnson & Johnson’s clinical, regulatory and strategic decisions evolve over time.
Johnson & Johnson (NYSE: JNJ) will attend the UBS Global Healthcare Conference on May 24, 2022. Mathai Mammen, Executive Vice President of Pharmaceuticals R&D, will represent the company during a session at 10:00 a.m. ET. Interested investors can access the live webcast and subsequent replay, which will be available approximately 48 hours later, through the Johnson & Johnson website.
Johnson & Johnson (NYSE: JNJ) reported Q1 2022 sales of $23.4 billion, a 5.0% increase, with operational growth at 7.7%. Adjusted earnings per share rose 3.1% to $2.67, while diluted EPS fell 16.8% to $1.93. The suspension of COVID-19 Vaccine sales guidance reflects a global supply surplus and demand uncertainty, though it won't affect adjusted operational EPS guidance. The Pharmaceutical segment drove growth, particularly from DARZALEX and STELARA. Consumer Health sales declined slightly, impacted by supply constraints, while MedTech saw an 8.6% increase in adjusted operational sales.
Johnson & Johnson (NYSE: JNJ) has declared a 6.6% increase in its quarterly dividend, raising it from $1.06 to $1.13 per share. This marks the 60th consecutive year of dividend increases, reflecting the company's strong financial position and future confidence. The annual dividend now stands at $4.52 per share, up from $4.24. Shareholders can expect the next dividend payment on June 7, 2022, with the record date on May 24, 2022 and ex-dividend date on May 23, 2022.
Johnson & Johnson (NYSE: JNJ) will participate in the BofA Securities 2022 Healthcare Conference on May 11 at the Encore Hotel in Las Vegas, Nevada. Ashley McEvoy, Executive Vice President and Worldwide Chairman of MedTech, will represent the company during a session at 3:40 p.m. ET. Investors can access the conference call and additional information via the Johnson & Johnson website. A replay of the webcast and podcast will be available approximately 48 hours after the live event.
Ventus Therapeutics has appointed Victor Lobanov, Ph.D., as Senior Vice President, Head of Computational Sciences, bringing over 25 years of experience in computational methods for drug discovery. Dr. Lobanov will lead the company's computational efforts and enhance the ReSOLVE platform while integrating machine learning and structural biology. His past roles include significant contributions at Johnson & Johnson (NYSE: JNJ) and Labcorp Drug Development (NYSE: LH). Ventus aims to leverage his expertise to optimize drug discovery processes, focusing on challenging protein targets.
Johnson & Johnson (NYSE: JNJ) will host a conference call on April 19, 2022, at 8:30 a.m. (ET) to discuss its first-quarter results. The call will be led by Joseph J. Wolk, Chief Financial Officer, and Jessica Moore, Vice President of Investor Relations, along with other executives.
Investors can access the call via webcast at www.investor.jnj.com, with a replay available three hours post-call. The press release will be issued at 6:45 a.m. (ET) on the same day.
Revelations have emerged regarding Johnson & Johnson (NYSE: JNJ) funding unethical experiments on prisoners during the 1960s, linking to the ongoing controversy over its talc-based products. The experiments involved primarily African-American inmates and raised concerns about the company’s knowledge of the cancer risks associated with its talc products like Johnson's Baby Powder. With the company attempting to limit jury trials through a bankruptcy move, many cancer victims are now seeking justice through litigation. Legal experts call for new laws to prevent corporations from evading liabilities through bankruptcy.
Pathalys Pharma, a late-stage biopharmaceutical company, has been established with seed financing from DaVita Venture Group and Catalys Pacific. The company focuses on chronic kidney disease (CKD) treatments, starting with the investigational drug upacicalcet, which has demonstrated efficacy in Japan. Pathalys plans to conduct two phase 3 clinical trials in the U.S. for upacicalcet to treat secondary hyperparathyroidism in hemodialysis patients. Neal Fowler, a former CEO at Liquidia, has been appointed as CEO, enhancing the leadership team's industry experience.
Johnson & Johnson (NYSE: JNJ) has appointed Darius Adamczyk, Chairman and CEO of Honeywell, to its Board of Directors, effective February 15, 2022. Adamczyk is recognized for his extensive business leadership and commitment to sustainability and innovation. His appointment is expected to enhance the board's diverse expertise and support JNJ's focus on creating healthier communities and delivering transformative health solutions. Adamczyk expressed his honor to join JNJ at a crucial time, emphasizing the company's values-driven mission to improve lives and create long-term stakeholder value.
Johnson & Johnson (NYSE: JNJ) will attend the Raymond James 43rd Annual Institutional Investors Conference on March 8, 2022. Joseph J. Wolk, Executive Vice President and CFO, will speak at 1:05 p.m. ET. Investors can view the session via a webcast on their official website, www.investor.jnj.com. A replay will be accessible approximately 48 hours after the live event.